Accelerating Human Evolution: H+ Dynamics Investor Pitch

H+ DYNAMICS

Accelerating Human Evolution Through Transhumanist Technology

The Problem: Biological Stagnation

Human evolution has stalled. While AI advances exponentially, biological limits—aging, cognitive thresholds, and physical fragility—hinder human potential. The global economy faces trillions in losses due to an aging workforce unable to compete with automation.

The History of Human Capability

2.5M Years Ago: Stone tools extend physical reach and force.

800k Years Ago: Control of fire maximizes energy for brain growth.

50k Years Ago: Complex language allows collective storage of knowledge.

21st Century: Direct neural interfacing (The H+ Era).

Values of Evolutionary Latency

Biological evolution is reactive and slow, taking millennia to adapt to environmental shifts. Cultural and technological evolution is proactive and exponential. We are bridging the gap to allow real-time biological adaptation.

The Solution: Integrated Augmentation

• Neural Implants: AI-driven cognitive expansion. • Biotech Optimization: Advanced HGH formulations for cellular repair. • Exoskeletons: Physical enhancement for 2x productivity. • Ecosystem: Open platform for personalized evolution.

Explosive Market Growth (TAM)

The Human Augmentation market is projected to reach $545.1B by 2028 with a CAGR of 16.5%. The Transhumanism specific sub-sector is growing even faster at 22.8% CAGR.

Business Model & Unit Economics

Hardware Sales (40%): Direct B2C/B2B sales of neural implants and exoskeletons.

Subscription Model (35%): Monthly recurring revenue for AI software upgrades and HGH supply.

Enterprise Licensing (20%): Healthcare and industrial training simulation platforms.

Economics: $2K Lifetime Value (LTV) per user with 60% estimated margins at scale.

Go-to-Market Strategy

Phased Global Rollout: 1. Year 1 (North America): Pilot programs in Silicon Valley & Major Hospitals (35% market share). 2. Year 2 (Asia-Pacific): Expansion into high-growth markets like China & Japan via online pharmacies. 3. Year 3+ (Global): Enterprise adoption and retail mass-market access.

Competitive Landscape

Neuralink: Strong AI focus but lacks broad biotech integration (HGH/Exos).

Pharma Giants (Pfizer/Novo Nordisk): Dominant in chemical therapy but minimal tech augmentation.

H+ Dynamics Advantage: The only holistic provider combining Biological + Technological evolution.

Financial Projections (2026-2030)

We project reaching $1B in revenue by 2030, driven by the $126B transhumanism market expanding at 22.8% CAGR. Breakeven expected in year 2.

Darwin's evolution took millions of years. We are delivering it in decades.

Vision Statement

Invest in the Next Step of Evolution

Seeking $10M Series A Funding Use of Funds: R&D, Clinical Trials, Market Expansion Contact: invest@hdynamics.com www.hdynamics.com